Blackstone Faces Regulatory Fine or Lengthy Appeal in TXNM Deal

Blackstone/TXNM Energy: PE Firm Likely Faces Tough Choice of Accepting Recommended Penalty or Extending Regulatory Process With Appeal

Private equity firm Blackstone (BX) probably faces a tough choice in its $11.5 billion bid for New Mexico power company TXNM Energy (TXNM): accept a utility regulator’s likely fine and order to unwind a $400 million stock purchase, or appeal that decision, extending the regulatory process into next year and maybe beyond

DOJ in Settlement Talks with Egg Producers Over Price-Coordination Concerns

DOJ’s antitrust division is engaged in settlement talks with the nation’s largest egg producers to resolve an ongoing investigation into potential industry price coordination, sources familiar...

Jun 10, 2026 Read Now >

Anglo American/Teck Resources: SAMR Starts In-depth Phase 3 Review of Copper Tie-up as Market Survey Continues

China’s antirust authority has launched an in-depth phase 3 review of London-based mining giant Anglo American’s (LSE: AAL) proposed acquisition of Canada’s Teck Resources (TECK), sources...

Jun 10, 2026 Read Now >

Health Care Weekly: SCOTUS Sides with Generic Drugmaker in Skinny Labeling Case; FDA, Congress Aim to Speed Up Investigational New Drug Applications; OpenEvidence Says Doximity Misled Pharmaceutical Advertisers; CMS to Launch GLP-1 Bridge Program in July; FDA 483s

SCOTUS rules in favor of generic drugmaker in “skinny labeling” case. On June 4, the Supreme Court issued a unanimous opinion to reverse a previous Federal Circuit ruling in a patent case filed...

Jun 10, 2026 Read Now >

Blackstone/TXNM Energy: PE Firm Likely Faces Tough Choice of Accepting Recommended Penalty or Extending Regulatory Process With Appeal

RELATED ARTICLES | Energy

DOJ in Settlement Talks with Egg Producers Over Price-Coordination Concerns

Anglo American/Teck Resources: SAMR Starts In-depth Phase 3 Review of Copper Tie-up as Market Survey Continues

Health Care Weekly: SCOTUS Sides with Generic Drugmaker in Skinny Labeling Case; FDA, Congress Aim to Speed Up Investigational New Drug Applications; OpenEvidence Says Doximity Misled Pharmaceutical Advertisers; CMS to Launch GLP-1 Bridge Program in July; FDA 483s

FILTER BY

This article is currently locked and only available to subscribers. Request a trial to receive unlimited access to all articles.